EGFR tyrosine kinase inhibitors (EGFR-TKIs) can prolong survival and improve the quality of life of patients with NSCLC with EGFR mutations (Ramalingam et al., 2020). This evidence concerns the gene EGFR and non-small cell lung carcinoma.